Effects of intrastriatal injection of the dopamine receptor agonist SKF38393 and quinpirole on locomotor behavior in hemiparkinsonism rats. 2021

Mengnan Guo, and Tianyu Xiang, and Min Li, and Yue Sun, and Shuang Sun, and Dadian Chen, and Qingmei Jia, and Yuchuan Li, and Xiaomeng Yao, and Xiaojun Wang, and Xiao Zhang, and Feng He, and Min Wang
Key Laboratory of Animal Resistance Biology of Shandong Province, College of Life Science, Shandong Normal University, Jinan, People's Republic of China.

Dopamine (DA) in the striatum is essential to influence motor behavior and may lead to movement impairment in Parkinson's disease (PD). The present study examined the different functions of the DA D1 receptor (D1R) and DA D2 receptor (D2R) by intrastriatal injection of the D1R agonist SKF38393 and the D2R agonist quinpirole in 6-hydroxydopamine (6-OHDA)-lesioned and control rats. All rats separately underwent dose-response behavior testing for SKF38393 (0, 0.5, 1.0, and 1.5 μg/site) or quinpirole (0, 1.0, 2.0, and 3.0 μg/site) to determine the effects of the optimal modulating threshold dose. Two behavior assessment indices, the time of latency to fall and the number of steps on a rotating treadmill, were used as reliable readouts of motor stimulation variables for quantifying the motor effects of the drugs. The findings indicate that at threshold doses, SKF38393 (1.0 μg/site) and quinpirole (1.0 μg/site) produce a dose-dependent increase in locomotor activity compared to vehicle injection. The ameliorated behavioral responses to either SKF38393 or quinpirole in lesioned rats were greater than those in unlesioned control rats. Moreover, the dose-dependent increase in locomotor capacity for quinpirole was greater than that for SKF38393 in lesioned rats. These results can clarify several key issues related to DA receptors directly and may provide a basis for exploring the potential of future selective dopamine therapies for PD in humans.

UI MeSH Term Description Entries
D008124 Locomotion Movement or the ability to move from one place or another. It can refer to humans, vertebrate or invertebrate animals, and microorganisms. Locomotor Activity,Activities, Locomotor,Activity, Locomotor,Locomotor Activities
D008297 Male Males
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015647 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine A selective D1 dopamine receptor agonist used primarily as a research tool. 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-,R-SK&F 38393,SK&F-38393,SKF 38393-A,SKF-38393,SKF38393,RSK&F 38393,SK&F 38393,SK&F38393,SKF 38393,SKF 38393 A,SKF 38393A

Related Publications

Mengnan Guo, and Tianyu Xiang, and Min Li, and Yue Sun, and Shuang Sun, and Dadian Chen, and Qingmei Jia, and Yuchuan Li, and Xiaomeng Yao, and Xiaojun Wang, and Xiao Zhang, and Feng He, and Min Wang
August 1994, Pharmacology, biochemistry, and behavior,
Mengnan Guo, and Tianyu Xiang, and Min Li, and Yue Sun, and Shuang Sun, and Dadian Chen, and Qingmei Jia, and Yuchuan Li, and Xiaomeng Yao, and Xiaojun Wang, and Xiao Zhang, and Feng He, and Min Wang
December 2008, Neuroscience letters,
Mengnan Guo, and Tianyu Xiang, and Min Li, and Yue Sun, and Shuang Sun, and Dadian Chen, and Qingmei Jia, and Yuchuan Li, and Xiaomeng Yao, and Xiaojun Wang, and Xiao Zhang, and Feng He, and Min Wang
January 1987, Fundamental & clinical pharmacology,
Mengnan Guo, and Tianyu Xiang, and Min Li, and Yue Sun, and Shuang Sun, and Dadian Chen, and Qingmei Jia, and Yuchuan Li, and Xiaomeng Yao, and Xiaojun Wang, and Xiao Zhang, and Feng He, and Min Wang
January 1993, Behavioural pharmacology,
Mengnan Guo, and Tianyu Xiang, and Min Li, and Yue Sun, and Shuang Sun, and Dadian Chen, and Qingmei Jia, and Yuchuan Li, and Xiaomeng Yao, and Xiaojun Wang, and Xiao Zhang, and Feng He, and Min Wang
January 2001, Pharmacology, biochemistry, and behavior,
Mengnan Guo, and Tianyu Xiang, and Min Li, and Yue Sun, and Shuang Sun, and Dadian Chen, and Qingmei Jia, and Yuchuan Li, and Xiaomeng Yao, and Xiaojun Wang, and Xiao Zhang, and Feng He, and Min Wang
September 1996, Psychopharmacology,
Mengnan Guo, and Tianyu Xiang, and Min Li, and Yue Sun, and Shuang Sun, and Dadian Chen, and Qingmei Jia, and Yuchuan Li, and Xiaomeng Yao, and Xiaojun Wang, and Xiao Zhang, and Feng He, and Min Wang
December 2009, European journal of pharmacology,
Mengnan Guo, and Tianyu Xiang, and Min Li, and Yue Sun, and Shuang Sun, and Dadian Chen, and Qingmei Jia, and Yuchuan Li, and Xiaomeng Yao, and Xiaojun Wang, and Xiao Zhang, and Feng He, and Min Wang
March 2004, Pharmacology, biochemistry, and behavior,
Mengnan Guo, and Tianyu Xiang, and Min Li, and Yue Sun, and Shuang Sun, and Dadian Chen, and Qingmei Jia, and Yuchuan Li, and Xiaomeng Yao, and Xiaojun Wang, and Xiao Zhang, and Feng He, and Min Wang
April 1996, European journal of pharmacology,
Mengnan Guo, and Tianyu Xiang, and Min Li, and Yue Sun, and Shuang Sun, and Dadian Chen, and Qingmei Jia, and Yuchuan Li, and Xiaomeng Yao, and Xiaojun Wang, and Xiao Zhang, and Feng He, and Min Wang
November 2007, Psychopharmacology,
Copied contents to your clipboard!